Immunotherapy represent an innovative and promising strategy for the treatment of MM, and various experimental drugs have been proposed such as monoclonal antibodies (e.g., against CTLA4, PD-1, and PD-L1) [23] and mesothelin-targeting agents (anticancer antibodies/antibodies-drug conjugates; mesothelin-targeting vaccines; mesothelin-targeting recombinant T cells). This evidence concerns the gene CTLA4 and Miyoshi myopathy.